HAE vs ITGR vs NVCR vs HOLX

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -2. 0% for Haemonetics Corporation (HAE). Haemonetics Corporation (HAE) offers the better valuation at 26. 5x trailing P/E (11. 0x forward), making it the more compelling value choice. Analysts rate Haemonetics Corporation (HAE) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Haemonetics Corporation (HAE) is the cheapest at 26.

5x versus Hologic, Inc. at 30. 5x. On forward P/E, Haemonetics Corporation is actually cheaper at 11. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Haemonetics Corporation wins at 0. 63x versus Integer Holdings Corporation's 3. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ITGR returned +165. 1% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 137% for Haemonetics Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -2. 0% for Haemonetics Corporation (HAE). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -38. 1% for Haemonetics Corporation. Over a 3-year CAGR, ITGR leads at 11. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Haemonetics Corporation (HAE) is the more undervalued stock at a PEG of 0. 63x versus Integer Holdings Corporation's 3. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Haemonetics Corporation (HAE) trades at 11. 0x forward P/E versus 17. 2x for Hologic, Inc. — 6. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.